Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01063920 · ClinicalTrials.gov registry record · Phase 2
Rates of Gastric Ulcer by Endoscopy in Knee Osteoarthritis Patients Receiving LT-NS001 Versus Naprosyn®
A Phase 2 study of Osteoarthritis, sponsored by Logical Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 534
- Enrollment target
- 20
- Study locations
NCT01063920: Completed Phase 2 study of Osteoarthritis, sponsored by Logical Therapeutics.
NCT01063920 is a Phase 2 study of Osteoarthritis that has completed, run by Logical Therapeutics. The registered enrollment target is 534 participants, below the 814-participant average among 135 other Osteoarthritis trials with a reported enrollment target (34% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01063920, a Phase 2 study of Osteoarthritis, has completed, sponsored by Logical Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 534 participants
- Enrollment target
- 20
- Study locations
Study Summary
LT-NS001 is a prodrug of Naproxen, which is inactive as a cox inhibitor while intact and is rapidly metabolized to Naproxen once absorbed. This trial will compare the rate of gastric ulcer by endoscopy over three months in patients with knee osteoarthritis, with patients receiving either LT-NS001 at a dose which provides comparable dose levels of Naproxen, or Naprosyn® 500mg (an approved treatment for OA).
Conditions Studied
Interventions
- DRUG LT-NS001
- DRUG Naprosyn®
Study Locations (20)
California
- Orange County Clinical Trials - Anaheim
- Theresa Sligh, MD - Burbank
- Torrance Clinical Research - Lomeita
- West Gastroenterology Associates - Los Angeles
- Facey Medical Center - Mission Hills
- Desert Medical Group - Palm Springs
- Medical Affiliated Research Center Inc. - San Diego
- Cynthia Schaeffer, MD - San Diego
- Medical Associates Research Group - San Diego
Arizona
- Radiant Research - Chandler
- Dedicated Clinical Research Inc. - Surprise
- Radiant Research Inc. - Tucson
- Adobe Gastroenterology Research, LLC - Tucson
- Genova Clinical Research Inc. - Tucson
Alabama
- Greystone Medical Research, LLC - Birmingham
- Clinical Research Associates - Huntsville
Colorado
- Lynn Institute of the Rockies - Colorado Springs
- Rocky Mountain Center for Clinical Research - Wheat Ridge
Arkansas
- Lynn Institute of the Ozarks - Little Rock
Florida
- Eastern Clinical Research Unit - Hialeah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 534 participants |
| Start Date | 2010-02 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
What the finished NCT01063920 record still lists
NCT01063920 is an interventional study that assigns participants to a tested intervention. The registered 534 participants enrollment target is mid-sized for trials with a published cap, below the 814-participant average among 135 other Osteoarthritis trials with a reported enrollment target (34% lower).
The record links to 1 condition, with Osteoarthritis appearing as the primary indexed condition, and to 2 interventions - of which LT-NS001 is the first listed.
NCT01063920 names 20 study sites across 6 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT01063920 about?
NCT01063920 is a clinical study titled "Rates of Gastric Ulcer by Endoscopy in Knee Osteoarthritis Patients Receiving LT-NS001 Versus Naprosyn®". LT-NS001 is a prodrug of Naproxen, which is inactive as a cox inhibitor while intact and is rapidly metabolized to Naproxen once absorbed. This trial will compare the rate of gastric ulcer by endoscopy over three months in patients with knee osteoarthritis, with patients receiving either LT-NS001 at...
What is the current status of trial NCT01063920?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 534 participants. The study started on 2010-02. Estimated completion is 2010-11.
What conditions does trial NCT01063920 study?
This clinical trial studies the following conditions: Osteoarthritis.
What interventions are being tested in trial NCT01063920?
The interventions under investigation include: LT-NS001 (DRUG), Naprosyn® (DRUG).
Who is sponsoring clinical trial NCT01063920?
This trial is sponsored by Logical Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01063920 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01063920's enrollment target sits among peer trials
534 28th of 135 higher than 108 of 135 other Osteoarthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoarthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Knee
RECRUITING · Phase 2
-
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Shoulder
RECRUITING · Phase 2
-
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Hip
RECRUITING · Phase 2
-
Platelet Rich Plasma Injections In Young And Old Human Subjects
RECRUITING · Phase 2
-
A Mobile Intervention to Reduce Pain and Improve Health-III
RECRUITING · Phase 2
-
An Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04910685 · 534 participants · Phase 2
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
- NCT06128551 · 534 participants · Phase 1
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- NCT05614739 · 535 participants · Phase 1
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
- NCT07091617 · 535 participants · NA
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia